NDAORALTABLET
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VICOPROFEN is a fixed-dose combination tablet containing hydrocodone bitartrate (an opioid analgesic) and ibuprofen (an NSAID) approved in 1997. It is indicated for short-term management of acute pain where the severity of pain requires an opioid analgesic and where an NSAID may provide additional benefit. The combination mechanism leverages opioid receptor agonism plus cyclooxygenase inhibition to provide multimodal analgesia.
LOE Approaching
As a late-lifecycle product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on defensive positioning and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VICOPROFEN offers experience in late-lifecycle brand management, generic defense strategy, and loss-of-exclusivity transition planning. Roles are primarily commercial and defensive in nature, with limited opportunity for pipeline expansion but significant opportunity to develop expertise in pricing, payer relations, and market positioning during maturity.
Brand Manager
Worked on VICOPROFEN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.